kabutan

Tsubota Laboratory Incorporated(4890) Summary

4890
TSE Growth
Tsubota Laboratory Incorporated
413
JPY
-12
(-2.82%)
Mar 13, 3:30 pm JST
2.59
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
404
Mar 13, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
9.64
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
433 JPY 2.71 USD
Previous Close Mar 12
425 JPY 2.67 USD
High Mar 13, 2:21 pm
478 JPY 2.99 USD
Low Mar 13, 10:26 am
365 JPY 2.29 USD
Volume
10,918,100
Trading Value
4.64B JPY 0.03B USD
VWAP
424.76 JPY 2.67 USD
Minimum Trading Value
41,300 JPY 259 USD
Market Cap
0.01T JPY 0.07B USD
Number of Trades
17,552
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Mid
1-Year Average
269
1-Year High Mar 13, 2026
17,552
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 0 567,500
Feb 27, 2026 0 567,800
Feb 20, 2026 0 587,500
Feb 13, 2026 0 650,900
Feb 6, 2026 0 615,600
Company Profile
Tsubota Laboratory Incorporated is a biotech venture originating from Keio University. The company focuses on research and development of pharmaceuticals for myopia, dry eye, presbyopia, and brain activation.
Sector
Pharmaceuticals
Tsubota Laboratory Incorporated, a biotech venture born out of Keio University School of Medicine, aims to create groundbreaking innovations in the treatment of myopia, dry eye, presbyopia, and brain-related disorders. The company conducts advanced research in collaboration with affiliated universities and pursues joint development with partner companies to evaluate research outcomes. Its business model is based on generating revenue through joint research and development agreements, licensing agreements, upfront payments, milestone payments, and post-commercialization royalties, which are then reinvested into new research in a cyclical manner. A distinctive feature of the company is its research and development utilizing the high-level expertise of external contracted researchers. Tsubota Laboratory Incorporated adopts a dual strategy, simultaneously developing and marketing pharmaceuticals and medical devices alongside commodity products.